Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07123103 · ClinicalTrials.gov registry record · Phase 1
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Solid Tumors, sponsored by Exelixis.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 9
- Study locations
NCT07123103 is a Phase 1 study of Solid Tumors that is actively recruiting participants, run by Exelixis. The registered enrollment target is 150 participants, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (47% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT07123103, a Phase 1 study of Solid Tumors, is actively recruiting participants, sponsored by Exelixis.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 9
- Study locations
Study Summary
The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.
Conditions Studied
Interventions
- DRUG XB371
Study Locations (9)
Texas
- Exelixis Clinical Site #8 - Houston
- Exelixis Clinical Site #1 - San Antonio
Arkansas
- Exelixis Clinical Site #5 - Rogers
California
- Exelixis Clinical Site #9 - Los Angeles
District of Columbia
- Exelixis Clinical Site #6 - Washington D.C.
Florida
- Exelixis Clinical Site #4 - Orlando
Michigan
- Exelixis Clinical Site #3 - Grand Rapids
New Jersey
- Exelixis Clinical Site #7 - New Brunswick
North Carolina
- Exelixis Clinical Site #2 - Huntersville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-08-18 |
| Est. Completion | 2028-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07123103
The ClinicalTrials.gov registry entry for NCT07123103 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (47% lower). The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which XB371 is the first listed.
NCT07123103 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Texas, Arkansas, California.
Frequently Asked Questions
What is clinical trial NCT07123103 about?
NCT07123103 is a clinical study titled "A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors". The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.
What is the current status of trial NCT07123103?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2025-08-18. Estimated completion is 2028-02.
What conditions does trial NCT07123103 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT07123103?
The interventions under investigation include: XB371 (DRUG).
Who is sponsoring clinical trial NCT07123103?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07123103 being conducted?
This trial has 9 study locations across Arkansas, California, District of Columbia, Florida, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.